OncLive.com路 @OncLive 路 X路路 3 days agoScore70
Body
馃珌 What lung cancer data could shape practice at #ESMO2026?
@BalazsHalmosMD and Dylan Fortman, MD of @umichmedicine, spotlight key SCLC and NSCLC trials, including DeLLphi-305, PERSEE, Krascendo 1, and SAFFRON.
Explore their picks: https://hubs.li/Q04BZgxl0
644 views 路 2 likes 路 0 reposts 路 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: OncLive.com 路 x.com